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The glycosylation profile of intact antibody due to the galactose and fucose heterogeneity in
the N-linked sugars was determined with instrument resolution of 5000 and 10,000. After
deconvolution of electrospray ionization mass spectra to complete convergence, several extra
peaks appeared in addition to the peaks observed in the original mass spectra. The artificial
peaks were avoided if deconvolution was stopped after a smaller number of iterations. A
standard antibody was used as an external calibrant to minimize mass measurement errors
during long-period experiments. Precision of four consecutive LC/MS measurements of the
same antibody was 10 ppm (1.5 Da). By using this approach, the masses of 11 intact
antibodies were measured. All antibodies containing N-terminal glutamines had a negative
mass shift due to the formation of pyroglutamate (17 Da). Although the pyroglutamate
variant of intact antibody was not resolved from the unmodified variant, this modification led
to a mass shift proportional to the percentage of N-terminal pyroglutamate. By accurately
measuring the mass shift we were able to quantify the abundance of pyroglutamic acid on
intact antibodies. Mass accuracy in measuring different antibodies was below 30 ppm (4 Da).
The accurate mass measurement can be an effective tool for monitoring chemical degradations
in therapeutic antibodies. (J Am Soc Mass Spectrom 2006, 17, 867–872) © 2006 American
Society for Mass SpectrometryIgG antibodies are heterodimers with molecularweight of approximately 150 kDa and are com-posed of two identical heavy chains and two
identical light chains linked together through disul-
fide linkages [1]. In addition to the protein compo-
nent, IgG molecules contain an N-linked biantennary
sugar in the conserved region on each heavy chain [2,
3]. The common post-translational modifications that
occur in vivo during production of mammalian re-
combinant antibodies include C-terminal lysine vari-
ants, glycosylation variants, and the formation of
N-terminal pyroglutamic acid. The C-terminal lysine
residues are often removed by the enzyme car-
boxypeptidase [4]. The earlier studies of several pro-
teins including antibodies, suggested that N-terminal
pyroglutamate (pE) is most likely formed either late
in protein translation by cyclization of N-terminal
glutamine (Q) or as a post-translational event just
before cellular secretion of protein from the cell [5, 6].
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doi:10.1016/j.jasms.2006.02.023In a recent study [7], a set of almost 300 secreted
recombinant human proteins was analyzed by Ed-
man analysis to examine frequency of amino acid at
the N-terminus. Glutamine was identified as the most
preferred N-terminal residue. It was found at the first
position in 10.7% of the proteins. The authors also
suggested that the frequently observed cyclization of
N-terminal Q to pE provides protection for the se-
creted proteins against degradation by extracellular
aminopeptidase [7]. Out of more than 200 human and
murine immunoglobulin heavy and light chains sub-
jected to amino terminal sequence analysis [8], Q
residues are largely converted to pE residues with
few exceptions [9]. The glutamic to pyroglutamic acid
conversion [5, 10] seems to be less often and, if
happens, takes place with slower rate than Q to pE.
N-terminal Q can be converted to pE during fermen-
tation process and during storage in pharmaceutics
with exposure to elevated temperatures and near
neutral pH [10, 11]. The cyclization was also detected
during peptide mapping, which is typically con-
ducted at pH 7.5 and 37 °C, the conditions which
facilitate formation of pE on N-termini of unfolded
peptides [12].
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due to their high molecular mass, hydrophobic nature,
and presence of sugar moieties. Conversely, LC/MS
analysis of intact protein is also advantageous because
it reduces dramatically the time for sample preparation
and data interpretation, compare with peptide map-
ping, and sequencing. Furthermore it also minimizes
the chance of introducing putative modifications, which
are often observed during peptide mapping. In this
paper, we discuss methods to improve mass accuracy of
IgG molecules and the utility of the improved mass
measurement for quantification of N-terminal pyroglu-
tamate.
Materials and Methods
Materials
Eleven recombinant monoclonal IgG antibodies used in
this study were produced and purified at Amgen.
N-terminal residues of heavy chains of seven antibodies
were glutamines, which are susceptible to conversion to
pyroglutamate. N-terminal residues of heavy chains of
four other antibodies and light chains of all antibodies
were either glutamic or aspartic acid residues, which
are stable with respect to cyclization. Trifluoroacetic
acid (TFA) was obtained from Pierce, Rockford, IL.
N-propanol (NPA) and water were obtained from Bur-
dick and Jackson, Muskegon, MI, no. 322-1.
Reversed-Phase Chromatography
The reversed-phase HPLC method was adopted from
reference[13] with minor modifications. Reversed-
phase separation was carried out using an Agilent 1100
series CapLC equipped with an Agilent Zorbax SB 300
C8 50  1 mm column. A g protein sample was
typically injected on the column. The column was
initially equilibrated with 90% Solvent A (0.1% aqueous
TFA) and 10% Solvent B (90% NPA and 0.1% aqueous
TFA) for 2 min followed by a 1 min step gradient from
5 to 21% B. Elution was achieved with a liner gradient
of 21 to 27% B over 20 min. The flow rate and temper-
ature were maintained at 50 l/min and 75 °C through-
out the run.
ESI-TOF Mass Spectrometry
Mass spectrometric analysis was carried out in a posi-
tive ion mode on a Waters LCT Premier and Waters
Q-TOF Micro orthogonal TOF instruments equipped
with an ESI source. The analyses on the LCT Premier
were carried out either in V or Wmode with instrument
resolution at 5000 and 10,000, respectively. The instru-
ments were calibrated in the m/z range of 2500 to 4000
using multiply charged ions of one of the studied
antibodies (IgG001) with a calculated MW value of
148,251.2 Da. ESI mass spectra were deconvoluted us-ing Waters MassLynx MaxEnt 1 software to obtain the
deconvoluted mass.
Results and Discussion
Figure 1 shows the calculated natural isotopic distribu-
tion and calculated peak profiles for the intact antibody
IgG001, with instrument resolution set at 5000 and
10,000. The calculations were performed using the Iso-
Pro software (Senko, M.W., http://members.aol.com/
msmssoft/REGISTER.HTM). For IgG001 antibody, the
natural isotopic distribution is 22 Da at the full width at
half maximum (FWHM). The calculated FMHW is
broadened, due to the limited resolving power of a
mass spectrometer, to 30 Da for resolution of 10,000 and
to 40 Da for resolution of 5000. Therefore, modifications
such as N-terminal pyroglutamic acid formation (17
Da) cannot be resolved on the intact IgG molecule.
However, these modifications should affect the peak
shape of the deconvoluted mass spectrum and shift the
measured mass of intact antibody.
The charge distribution profiles of antibody IgG001 in
V and W modes are shown in Figure 2a. The various
peaks observed in the mass (m/z) spectra in Figure 2a
represent successive charge states of the molecular ions of
IgG001. These peaks were used to calibrate the mass (m/z)
scale of orthogonal TOF mass spectrometers used in this
study. We found that the best mass accuracy for intact
antibodies was achieved when the instruments were cal-
ibrated with an intact antibody and in the samem/z range.
The total number of protein ions reaching the detector was
approximately two times lower in the W mode compared
with the V mode, which was anticipated because of the
additional ion scattering in the flight tube in W mode. It
Figure 1. Calculated peak profile for the intact antibody, IgG001,
which has an elemental composition of C6516 H10034 N1706
O2082 S52 and a calculated average molecular weight of 147251.2
Da. Calculations were performed with IsoPro software using the
following parameters: 1  106 molecules; empirical type; all other
were default parameters. The calculated peak profiles from nar-
row to wide are shown as follows: natural isotopic distribution
(vertical peaks), profile for instrument resolution of 10,000 (solid
red contour line), and 5000 (dashed blue contour line).was observed that peaks with lower charge state (z)
869J Am Soc Mass Spectrom 2006, 17, 867–872 MASS ACCURACY OF INTACT ANTIBODIESFigure 2. (a) Positive ion ESI mass spectra of an intact monoclonal antibody IgG001, acquired in Vmode
with resolution 5000 and W mode with resolution 10,000. The deconvolution range is marked as a
double-headed arrow. Ion intensity is in the right top corner. (b) Positive ion ESI mass spectra for 46
charged ion of an intact monoclonal antibody IgG001 acquired in V mode and W mode. Peak labels
represent various glycoforms described in detail in Table 1. (c) Deconvoluted ESI mass spectra of an intact
monoclonal antibody IgG001 acquired using V and W modes containing multiple peaks due to the sugar
heterogeneity. The following MaxEnt parameters were used for data processing: mass range, 140,000 to
160,000 Da; minimum intensity ratio left and right, 50%; width at half height for uniform Gaussian model,
1.0; number of iterations, 8. Peak labels represent various glycoforms (see Table 1). (d) Deconvoluted ESI
mass spectra of an intact monoclonal antibody IgG001 acquired using V and Wmodes. Deconvolution of
the multiply changed ions was performed to complete convergence (40 iterations). Peaks labeled with an
asterisk (*) are artifacts of deconvolution. For deconvolution, width at half height for uniform Gaussian
model was 1.4 for V mode and 1.2 for Wmode. The different width values were chosen to better illustrate
shift of the artificial peaks. All other deconvolution parameters were the same as in (c).
870 GADGIL ET AL. J Am Soc Mass Spectrom 2006, 17, 867–872exhibit tailing, presumably due to solvent adducts of TFA
(114 Da) and mass resolution of these peaks was lower
compare to the peaks with higher z. It was also observed
that the tailing was more pronounced in V mode (Figure
2a). Hence, higher z (lower m/z) peaks were used for
deconvolution. The minor satellite peaks in Figure 2a with
slightly lower mass than the major peaks are due to the
antibody molecules with only one sugar moiety. This was
a unique modification of this lot of IgG001, not typical for
other antibodies.
The ESI mass spectra acquired in V andWmodes near
a molecular ion with charge 46 in the middle of the
deconvolution range are shown in Figure 2b. The sugar
profile is typical for antibodies and generated by the loss
of terminal galactose (162 Da) and fucose (146 Da) resi-
dues (Table 1) similar to profiles in reference [3]. FWHM
value of the peaks is 1.8 Da for this ion at m/z 3200 Da,
which corresponds to mass resolution of 1800. Figure 2c
contains the ESI mass spectra of IgG001 deconvoluted in
the range from m/z 2900 to 3500 by using a defined
number of iterations, eight. Figure 2b and c show, that the
V andWmodes provide similar resolution of the peaks of
glycosylation profile. Deconvolution of the multiply
charged ions from the higher m/z range (for example, m/z
3800–4800) produced broader peaks and more tailing,
especially for V mode (data not shown).
Deconvolution is a process of transformation of
multiply charged electrospray ions (seen in Figure 2a)
into MW value of an analyte using a software algorithm
[14 –16]. In Figure 2c, the deconvolution was stopped
Table 1. Structures of N-linked sugars commonly found in IgG
molecules. Each antibody typically has two glycans, one on each
heavy chain
Code Oligosaccharide structure
Average
mass
G2F
G—GN—M
G—GN—M
G—GN—M
M—GN—GN—
F
1769.6
0341.641esocuFF
4241.261esoculGG
4241.261esonnaMM
0591.302enimasoculglyteca-NNG
G1F
GN—M
M—GN—GN—
F
1607.5
G0F M—GN—GN—
F
1445.4
G0
GN—M
GN—M
GN—M
GN—M
M—GN—GN— 1299.3
Codes are adapted from reference [3].after eight iterations when peak width was approxi-mately equal to the calculated FWHM values (30 to 40
Da) shown in Figure 1. The deconvoluted mass spectra
in Figure 2c correlate well with the original ESI mass
spectra in Figure 2b, and have the same number of
peaks and similar intensity ratios. No major differences
in glycosylation profiles were observed in the spectra
acquired in V and W modes. Figure 2d shows the
deconvoluted ESI mass spectra for IgG001 deconvo-
luted to convergence, when the omega value reaches
one. After deconvolution to convergence, several extra
peaks appeared. We suggest that these extraneous
peaks are artifacts of the deconvolution algorithm be-
cause they are not visible on the original ESI mass
spectra shown in Figure 2b. Although the peaks due to
the galactose variants remain approximately the same
in Figure 2d, the putative peaks shift in mass and
intensity. The putative peaks shift when switching from
V to W mode and also when width at half height used
for deconvolution changes, for example, from 1.4 Da in
V mode to 1.2 Da in W mode in Figure 2d. Several
deconvolution artifacts and their sources have been
described in the literature, including (1) synthetic
“overtone” corresponding to doubling, tripling, etc. of
both the molecular mass and the number of charges,
and fractional charges [14]; (2) side peaks closest to the
molecular mass peak M, which occur at [(imax  1)/
imax]M, where imax is the highest number of charges
used for deconvolution [14]; and (3) when two or more
different species or impurities are present in the sample
[15]. It seems that the artificial peaks near the molecular
peaks described in this paper do not belong to the above
categories. We attribute these artificial peaks to the
periodic galactose peaks separated by 162 Da. These
glycosylation peaks introduce an unexpected (and not
completely understood at this time) challenge to the
deconvolution algorithm. It should be noted, that the
artificial peaks were not observed in the deconvoluted
mass spectra of our other protein molecules, which do
not possess the heterogeneity caused by sugar moieties
as, for example, in cytochrome c in reference [14].
In mass spectrometry, precision improves with the
increasing ion count and, therefore, increasing amount
of injected sample. We usually inject 4 g of the
protein, to produce the ion intensity above 40, which is
equivalent to 105 of multiply charged IgG ions ac-
quired between m/z 2500 to 4000. Injection of higher
amounts of protein leads to broadening of the chro-
matographic peak, carryover, and nonlinear response of
UV detector.
Fluctuations of ambient temperature can affect the
mass accuracy of TOF instruments by causing elonga-
tion of the flight tube with increasing temperature.
Variations may also be caused by a high voltage drift
during heating of power supplied and by other voltage
fluctuations. Many commercial TOF mass spectrome-
ters are equipped with an automatic temperature cor-
rection function. For example, 70 ppm/ °C was a typical
temperature correction coefficient for Waters Q-TOF
Micro and 33 ppm/ °C for LCT Premier used in this
871J Am Soc Mass Spectrom 2006, 17, 867–872 MASS ACCURACY OF INTACT ANTIBODIESstudy. When the coefficient was chosen correctly and
ambient temperature fluctuations in the room were not
large, the precision of mass measurements was around
1.5 Da. It was measured from deconvoluted ESI mass
spectra like in Figure 2c. After four consecutive injec-
tions of the same antibody, standard deviation of mass
measurements of peaks G0F/G0F, G1F/G0F, and G1F/
G1F was equal to 1.5, 1.1, and 3.8, correspondently (data
not shown). To compensate for possible mass devia-
tions caused by larger temperature fluctuations and
other instrument variations that may occur during
long-term operation, we periodically injected external
standard (IgG001) antibody to generate a calibration
curve, which was utilized to correct the measured
masses of unknown antibodies injected in the same
series. The long-period mass fluctuations (within days)
were within 3 Da.
MW values for the ten monoclonal antibodies were
measured according to the described procedure and
plotted as a deviation from the calculated MW values in
Figure 3. The measured MW values of four antibodies
(IgG001, IgG004, IgG005, and IgG011), which possessed
only N-terminal glutamic acid residues (E), were within
4 Da from their calculated MW values, including4 Da
for IgG004, 2 Da for IgG005, and 4 Da for IgG011.
Presuming that these four antibodies do not have any
other modifications, mass accuracy was within 4 Da or
30 ppm. This value (4 Da) was used as the error bar in
Figure 3. The source of this error can be attributed to
different glycosylation profiles and distributions of
multiply changed ions of the different antibodies. Note
that the 30-ppm mass accuracy determined for different
antibodies is different from the 10-ppm precision mea-
sured by multiple injections of the same antibody. The
other seven antibodies, each containing two N-terminal
glutamine residues (Q) on heavy chains, showed de-
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Figure 3. Mass differences (m) between the measured and
calculated MW values of eleven different intact antibodies. The
correction was made using the calibration curve for a monoclonal
antibody IgG001, which was used as an external standard. Letters
E and Q next to each antibody indicate the presence of either
glutamic acids or glutamine residues at the N-termini of the two
heavy chains of intact antibody. The N-terminal glutamine resi-
dues are susceptible to conversion to pyroglutamic acids with
mass decrease by 17 Da per chain, or total mass decrease of 34 Da
for two chains. The light chains of all antibodies have N-terminal
glutamic acid and aspartic acid residues, which are stable with
respect to the cyclization.creases in MW values close to 34 Da. N-terminal pyro-glutamic acid formation, which leads to a loss of 17
Da on one heavy chain and hence a total mass shift of
34 Da on the intact molecule including two heavy
chains, was identified as the source of the mass reduc-
tion. The percentage of N-terminal pyroglutamate was
estimated as following. For example, the corrected MW
value of the antibody IgG009 was 30 Da below the
calculated MW value. The 30 Da mass difference
observed for IgG009 corresponds to a mixture of 88%
pyroglutamate and 12% glutamate (Table 2). The largest
percentage of the remaining N-terminal glutamine of
36% was measured on antibody IgG010 (Figure 3 and
Table 2). The relative abundance of the N-terminal
glutamine and pyroglutamic acid residues was con-
firmed by other analytical methods [17].
Conclusions
LC/MS analysis of intact proteins using ESI orthogonal
TOF mass spectrometry is a useful tool for the analysis
of monoclonal antibodies. ESI-TOF MS allows for the
characterization of various sugar forms that are typi-
cally found in antibodies. The best mass resolution was
achieved for ions with higher charge states (lower m/z
value). Peak tailing and broadening was observed for
the lower changed states, especially in V mode, proba-
bly due to the solvents adducts of TFA. After deconvo-
lution to complete convergence, artificial peaks ap-
peared among the periodic glycosylation peaks. They
were eliminated by interrupting the deconvolution after
a limited number of iterations (typically eight). For
LC/MS analysis of intact antibodies, precision of mass
measurements after four consecutive injections of the
same antibody was 10 ppm (1.5 Da), and mass accu-
racy in measuring different antibodies was 30 ppm (4
Da). These values were achieved by calibrating mass
spectrometer with a standard antibody of similar mass
and in the same m/z range, by periodically injecting a
standard antibody to correct for possible long-term
mass fluctuations, and by injecting 4 g of protein for
high signal intensity. The improved mass accuracy
allowed analysis of modifications such as N-terminal
pyroglutamic acid formation (17 Da) on intact anti-
body despite the fact that this modification cannot be
Table 2. The percentage of N-terminal pyroglutamic acid
derived from the mass difference between the measured and
calculated MW values ( m) in Figure 3
% pyroglu
IgG002 91
IgG004 80
IgG007 104
IgG008 88
IgG009 110
IgG010 87
IgG011 64An error of 12% should be used based on mass accuracy of intact
antibody of 4 Da.
872 GADGIL ET AL. J Am Soc Mass Spectrom 2006, 17, 867–872resolved by MS. The N-terminal glutamine residues of
recombinant monoclonal IgG antibodies are almost
completely converted to pyroglutamic acid during pro-
duction process.
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